Abstract
Recombinant human granulocyte colony-stimulating factor (G-CSF) has been used for treatment of febrile neutropenia in systemic lupus erythematosus (SLE) and other systemic rheumatic diseases. We describe 2 patients with SLE with disease flares with irreversible loss of renal function in association with G-CSF therapy. Eighteen patients with SLE treated with G-CSF for neutropenia have been reported, of whom 4 developed mild disease flares or cutaneous vasculitis. Our experience suggests that G-CSF therapy should be used with considerable caution in patients with SLE.
Publication types
-
Case Reports
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adult
-
Autoimmune Diseases / chemically induced*
-
Autoimmune Diseases / prevention & control
-
Female
-
Granulocyte Colony-Stimulating Factor / adverse effects*
-
Granulocyte Colony-Stimulating Factor / therapeutic use*
-
Humans
-
Lupus Erythematosus, Systemic / complications
-
Lupus Erythematosus, Systemic / drug therapy*
-
Middle Aged
-
Recombinant Proteins
-
Recurrence
-
Renal Insufficiency / chemically induced*
-
Renal Insufficiency / prevention & control
-
Treatment Outcome
-
Vasculitis / chemically induced*
-
Vasculitis / prevention & control
Substances
-
Recombinant Proteins
-
Granulocyte Colony-Stimulating Factor